NCT06478693View on ClinicalTrials.gov

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

May 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

MT-303

MT-303

Trial Locations (7)

2010

RECRUITING

St Vincent's Hospital, Sydney

3004

RECRUITING

The Alfred Hospital, Melbourne

4102

RECRUITING

Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba

6150

RECRUITING

Linear Clinical Research, Murdoch

Unknown

RECRUITING

Pusan National Univesity Hospital, Busan

RECRUITING

Cha University Bundang Medical Center, Gyeonggi-do

ACTIVE_NOT_RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Myeloid Therapeutics

INDUSTRY